PHARMACY

Hy-Vee brings Rx-free naloxone to Minnesota stores

BY David Salazar

Hy-Vee is teaming up with the  to bring prescription-free naloxone to its stores in the Land of 10,000 Lakes. The health department provided the physician-signed protocol that allows a designated pharmacy or pharmacy chain’s pharmacist to dispense the opioid overdose reversal drug to patients without needing a prescription.

“We are very pleased that the Minnesota Department of Health has this opportunity to work with Hy-Vee to expand access in Minnesota to naloxone, a life-saving drug,” the department’s medical director Ruth Lynfield said.

Hy-Vee will offer naloxone in both injectable and nasal spray forms, the West Des Moines, Ia.-based company said. It added that when dispensing the drug, pharmacists will coach patients and family members on how to recognize signs of an opioid overdose and how to administer the medication.

“We know the availability of this medication has the potential to save lives,” Hy-Vee senior vice president and chief health officer Kristin Williams said. “It’s vital to do everything we can to assist a loved one who may encounter an opioid overdose by combining medications or by accidentally taking too much of a medication, being unaware of the life-threatening results.”

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Glenmark’s Clobex Spray generic

BY David Salazar

Glenmark Pharmaceuticals has received Food and Drug Administration approval for its generic Clobex Spray (clobetasol propionate spray, 0.05%). The drug is a corticosteroid indicated to treat moderate-to-severe plaque psoriasis in patients 18 years old and older.

Glenmark said that it will manufacture its Clobex Spray generic at its Baddi plant in India. The drug’s market saw sales of roughly $30.5 million for the 12 months ended January 2018, based on IQVIA sales data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Generic Aloxi launches from Dr. Reddy’s

BY David Salazar

Dr. Reddy’s Laboratories has introduced its generic Aloxi (palonosetron hydrochloride injection). The drug, which had been previously approved by the Food and Drug Administration, is indicated to treat chemotherapy-induced nausea and vomiting in adults.

Dr. Reddy’s generic Aloxi will be available in 0.25 mg/5 ml dosage strength. It will be packaged in a carton containing one single-dose vial. The drug’s market size is roughly $446 million for the 12 months ended January 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?